GSK (GSK) announced that GSK5764227, GSK’227, its B7-H3-targeted antibody-drug conjugate, ADC, has received Orphan Drug Designation, ODD, from the European Medicines Agency, EMA, for the treatment of pulmonary neuroendocrine carcinoma, NEC, a category of cancer that includes small-cell lung cancer, SCLC. The ODD was supported by preliminary clinical data showing durable responses in patients with extensive stage SCLC, ES-SCLC, who were treated with GSK’227 in the phase I ARTEMIS-001 clinical trial.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GSK:
- GSK’s New Phase 3 Study on Efimosfermin Alfa: A Potential Breakthrough for MASH Treatment
- GSK’s New Phase 3 Study on Efimosfermin Alfa: A Potential Game-Changer for Liver Disease Treatment
- GSK’s Promising New Cancer Study: A Closer Look for Investors
- GSK Launches New Phase 3 Study for Promising GIST Treatment
- GSK’s Promising Phase 2 Study on Efimosfermin for MASH-related Cirrhosis